<DOC>
	<DOCNO>NCT01277718</DOCNO>
	<brief_summary>This Phase 1 , single-center , open-label , randomize , 3-period , 2-sequence crossover study cobimetinib healthy participant evaluate effect proton-pump inhibitor ( PPI ) rabeprazole relative bioavailability cobimetinib healthy participant administer fed fast state .</brief_summary>
	<brief_title>A Study Evaluate Effect Proton-Pump Inhibitor ( Rabeprazole ) Relative Bioavailability Cobimetinib Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<criteria>Inclusion Criteria With body mass index range 18.5 29.9 kilogram per meter square ( kg/m^2 ) In good health , determine clinically significant finding medical history , 12lead electrocardiogram ( ECG ) , vital sign Clinical laboratory evaluation within reference range test laboratory Negative test select drug abuse Screening ( include alcohol ) Checkin Negative hepatitis panel ( include hepatitis B virus surface antigen [ HBsAg ] hepatitis C virus antibody [ antiHCV ] ) negative human immunodeficiency virus ( HIV ) antibody screen Healthy male females nonchildbearing potential agree use effective contraception Exclusion Criteria Significant history clinical manifestation significant metabolic , allergic , dermatological , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , neurological , psychiatric disorder History significant hypersensitivity , intolerance , allergy drug compound , food , substance History stomach intestinal surgery resection would potentially alter absorption and/or excretion orally administer drug , except appendectomy , hernia repair , and/or cholecystectomy allow History presence abnormal ECG History alcoholism drug addiction within 1 year prior Period 1 Checkin Use tobacco nicotinecontaining product within 6 month prior Period 1 Checkin Participation investigational study drug trial receipt investigational study drug occur within 30 day 5 halflives , whichever longer , prior Period 1 Checkin Use prescription medications/products within 14 day prior Period 1 Checkin Use overthecounter , nonprescription preparation within 7 day prior Period 1 Checkin Use alcohol , grapefruit , caffeinecontaining food beverage within 72 hour prior Period 1 Checkin Poor peripheral venous access Any acute chronic condition would limit participant 's ability complete and/or participate clinical study Female participant pregnant , lactating , breastfeed Use PPIs histamine H2 receptor antagonist within 1 month prior Period 1 Checkin Known hypersensitivity rabeprazole component derive product benzimidazoles Predisposing factor retinal vein occlusion ( RVO )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>